BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Saliva Diagnostic Systems (SALVE) Announces New COO


10/19/2005 5:10:34 PM

NEW YORK, May 4 /PRNewswire-FirstCall/ -- Saliva Diagnostic Systems, Inc. (BULLETIN BOARD: SVAD) is pleased to announce the appointment of Mr. D. Bruce Pattison as President and Chief Operating Officer, effective May 2, 2005. Mr. Pattison has been working closely with the Company as a consultant over the past five months. Mr. Pattison has over thirty years experience with technology based, health-care companies serving both diagnostic and therapeutic market segments. During the 1970's he held several senior management positions with the medical diagnostic and device division of Corning Glass Works. After leaving Corning, Mr. Pattison was President of three start-up companies involved with innovative drug-delivery products. At the Infusaid Corporation during the 1980's, Mr. Pattison led the regulatory approval and commercialization of two unique medical products: the industry's first implantable pump and the first vascular access port. Most recently, Mr. Pattison negotiated the sale of Arrow International's drug delivery business to Johnson & Johnson and then joined J&J as Executive Director of Drug Delivery.

Mr. Pattison stated: "The potential of the SDS technology platform is enormous. Every day the need for effective point-of-care testing for infectious diseases is becoming more apparent to the medical community, not only in the USA but worldwide. I believe the company's proprietary technology provides an elegant, safe, accurate, and easy to use solution to the needs of this rapidly growing market."

About Saliva Diagnostic Systems (SDS)

Saliva Diagnostic Systems manufactures and markets a patented rapid point of care testing device for infectious diseases, as well as oral fluid specimen collection devices using a patented volume adequacy indicator for drugs of abuse testing and other clinical uses. These products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations. Please visit our website at http://www.salv.com/

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts are forward- looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and the demand for the Company's products. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC").

Saliva Diagnostic Systems, Inc.

CONTACT: Investor Relations of Saliva Diagnostic Systems, Inc.,+1-508-655-0991



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->